Azitra Reports Q3 2026 Net Loss of $2.95 Million and Advances ATR-04 Trial

Azitra reported a net loss of $2.95 million for the third quarter of 2026, compared with $2.76 million a year earlier, while cash and cash equivalents stood at $3.75 million at quarter-end. The company advanced its ATR-04 clinical program and reported positive ex vivo findings for ATR-COSF. Azitra…